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Abstract
Background: Cells can be primed by external stimuli to obtain a long-term epigenetic memory. We hypothesize
that long-term exposure to elevated blood lipids can prime circulating immune cells through changes in DNA
methylation, a process that may contribute to the development of atherosclerosis. To interrogate the causal
relationship between triglyceride, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL)
cholesterol levels and genome-wide DNA methylation while excluding confounding and pleiotropy, we perform a
stepwise Mendelian randomization analysis in whole blood of 3296 individuals.
Results: This analysis shows that differential methylation is the consequence of inter-individual variation in blood
lipid levels and not vice versa. Specifically, we observe an effect of triglycerides on DNA methylation at three CpGs,
of LDL cholesterol at one CpG, and of HDL cholesterol at two CpGs using multivariable Mendelian randomization.
Using RNA-seq data available for a large subset of individuals (N = 2044), DNA methylation of these six CpGs
is associated with the expression of CPT1A and SREBF1 (for triglycerides), DHCR24 (for LDL cholesterol) and
ABCG1 (for HDL cholesterol), which are all key regulators of lipid metabolism.
Conclusions: Our analysis suggests a role for epigenetic priming in end-product feedback control of lipid
metabolism and highlights Mendelian randomization as an effective tool to infer causal relationships in
integrative genomics data.
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Background
External stimuli, including tobacco smoke [1], prenatal
malnutrition [2], and ultraviolet radiation [3], can induce
persistent changes in the epigenome. Circulating im-
mune cells are continuously exposed to a range of stim-
uli present in plasma. Infectious agents or oxidized low-
density lipoprotein (LDL) have been shown to affect the
epigenome of monocytes, which, as a result, became
protected against secondary infections [4] or acquired a
pro-inflammatory phenotype [5], respectively. Here,
we investigated whether circulating immune cells are
primed by blood lipids in vivo, a process potentially
relevant for the development of atherosclerosis, which
is driven by the interaction between lipids and the
immune system [6].
Various population studies have reported on the asso-
ciation between inter-individual variation in blood lipid
levels and genome-wide DNA methylation, a key com-
ponent of the epigenome, in circulating immune cells
[7–9]. Although sometimes interpreted as a causal effect
of DNA methylation on lipid levels [7], such epigenome-
wide association studies (EWASs) cannot distinguish
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cause and consequence [10]. Large genome-wide associ-
ation studies (GWASs), however, yielded sets of single
nucleotide polymorphisms (SNPs) that are robustly
associated with lipid levels [11]. Since genetic variants
cannot be the consequence of phenotypic variation,
lipid-associated SNPs can serve as causal anchors to
test whether elevated lipid levels induce DNA methy-
lation changes in immune cells using Mendelian
randomization (MR) [12–14].
To study whether blood lipids can epigenetically prime
circulating immune cells, we performed a systematic MR
analysis of triglycerides (TGs), LDL cholesterol (LDL-C),
and high-density lipoprotein (HDL) cholesterol (HDL-C)
levels using whole blood samples of 3296 individuals to
interrogate the causal relationship between lipid levels
and DNA methylation, while excluding confounding and
pleiotropy. Using this approach to analyze both DNA
methylation and transcriptome data from 2044 individ-
uals, we identified specific differences in DNA methyla-
tion that are induced by blood lipids and could be linked
to expression of genes with a well-established role in
lipid metabolism.
Results
The association between blood lipids and genome-wide
DNA methylation in whole blood was investigated in
3296 individuals from six cohorts (Table 1; the six co-
horts are in the Biobank-based Integrative Omics Study
(BIOS) Consortium, a full list of the authors of which is
available in Additional file 1). All cohorts were com-
prised of men and women (32–60 % men) and the age
of the individuals ranged from 18 to 81 years.
First, we performed EWASs of TG, LDL-C, and HDL-C
levels for 453,109 CpGs (Fig. 1a and Additional file 2). For
TG, we observed 21 differentially methylated CpGs (false
discovery rate (FDR)-adjusted P value <0.05; Table 2) with
effect sizes ranging from −0.9 to +2.4 % change in DNA
methylation per standard deviation (SD) difference in TG
levels. For LDL and HDL levels, we found three and four
differentially methylated CpGs with effect sizes ranging
from 0.4–1.0 % per SD and 0.2–0.7 % per SD, respectively.
The direction of the observed associations were consistent
across the six cohorts (Additional file 3). The EWAS effect
size estimates were not sensitive to the exclusion of non-
fasted samples (24 % of the individuals), the exclusion of
samples with imputed cell counts (15 % of the individ-
uals), or the addition of current smoking behavior, lipid-
lowering medication, or body mass index (BMI) as covari-
ates (Additional file 4).
EWASs are prone to bias due to unmeasured con-
founding and, crucially, cannot be used to infer whether
the associations arise from an influence of lipids on
DNA methylation or DNA methylation on lipids. To
address these limitations, we performed a MR analysis
to determine causality while excluding confounding
(Fig. 1b). We constructed weighted polygenic scores
(PSs) for TG, LDL-C, and HDL-C levels (Additional file 5)
using genetic variants identified in a large-scale meta-
analysis of GWASs of lipid levels [11] and evaluated
their validity in our own data (i.e., an F-statistic >10
and no association with known confounders). The PSs
for TG (30 SNPs), LDL-C (28 SNPs), and HDL-C (60
SNPs) explained a relatively small, but highly significant,
proportion of the variance (5.6 % [F = 157, P = 1.7 × 10−40],
3.1 % [F = 99, P = 6.2 × 10−27] and 5.1 % [F = 164, P = 1.1 ×
10−36]; Additional file 6) and were not associated with
confounders (Additional file 7) with the exception of the
HDL-C PS, which was associated with confounder neutro-
phil counts (P value = 1.8 × 10−2). However, the level of
statistical significance was very weak when compared with
the association between HDL-C PS and HDL-C levels.
Using the PSs as unbiased predictors of lipids levels, we
Table 1 Characteristics of the six cohorts in the BIOS Consortium
CODAM LL LLS NTR PAN RS
Number of individuals 164 748 785 692 184 723
RNA-Seqa 159 616 650 619
Gender (% male) 50 42 48 32 60 42
Age (years) [SD] 65.6 [6.8] 45.6 [13.3] 58.4 [7.5] 34 [12.1] 62.4 [9.4] 67.6 [6.0]
TG (mmol/L) [SD] 1.6 [0.8] 1.2 [0.9] 1.9 [1.2] 1.3 [0.7] 1.9 [1.1] 1.5 [0.9]
LDL-C (mmol/L) [SD] 3.6 [1.0] 3.0 [0.9] 3.4 [1.0] 2.8 [0.8] 3.4 [0.9] 3.3 [0.9]
HDL-C (mmol/L) [SD] 1.3 [0.3] 1.5 [0.4] 1.4 [0.4] 1.4 [0.9] 1.4 [0.4] 1.5 [0.4]
Monocytes (%) [SD] 7.9 [1.6] 8.5 [2.2] 5.5 [1.5] 7.7 [2.0] 6.8 [1.1] 7.1 [2.1]
Lymphocytes (%) [SD] 51.2 [14.0] 34.5 [7.4] 29.2 [6.9] 35.1 [7.8] 31.8 [7.1] 36.3 [7.9]
Neutrophils (%) [SD] 40.7 [6.9] 53.3 [8.0] 59.8 [7.7] 52.6 [7.7] 55.3 [7.0] 48.3 [7.1]
aThe number of individuals for which RNA-Seq data were available
CODAM Cohort on Diabetes and Atherosclerosis Maastricht, LL LifeLines, LLS Leiden Longevity Study, NTR Netherlands Twin Register, PAN Prospective ALS Study
Netherlands, RS Rotterdam Study, SD standard deviation
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Fig. 1 Illustration of the stepwise Mendelian randomization approach. a In a conventional EWAS, associations observed are potentially
confounded (C) and the direction of the association between lipids (L) and DNA methylation (M) cannot be inferred. b Using Mendelian
randomization, polygenic scores (P) are used to obtain an unconfounded proxy for lipid levels and, since M cannot influence P, an effect
of L on M can be inferred. c An additional analysis is required to exclude a direct effect of P on M (i.e., cis-methylation quantitative trait
loci (QTL) effect of polygenic score SNPs) not mediated through L. d Reverse causation, i.e., an effect of M on L, is excluded by evaluating the
association of local genetic variation (S) affecting M (cis-methylation QTL) on lipid levels. e Pleiotropic effects are excluded using a multivariate
model that incorporates all lipids and their polygenic scores
Table 2 Associations between log TG, LDL-C, and HDL-C levels and DNA methylation
Chromosome Position Mean DNAm (%) Estimate (%/SD)a PFDR
TG cg14476101 1 120,255,993 63 −0.8 (−1.0, −0.6) 2.6 × 10−8
cg19693031 1 145,441,553 73 −0.6 (−0.8, −0.5) 5.2 × 10−9
cg06690548 4 139,162,809 85 −0.6 (−0.7, −0.5) 5.7 × 10−12
cg05575921 5 373,379 79 −0.9 (−1.3, −0.6) 4.3 × 10−3
cg14817490 5 392,921 32 −0.5 (−0.6, −0.3) 3.3 × 10−2
cg06560379 6 44,231,306 12 −0.2 (−0.2, −0.1) 4.0 × 10−2
cg19589396 8 103,937,375 69 −0.4 (−0.5, −0.2) 7.6 × 10−3
cg07504977 10 102,131,013 41 0.5 (0.3, 0.6) 2.4 × 10−4
cg11376147 11 57,261,199 21 −0.2 (−0.3, −0.1) 7.3 × 10−3
cg00574958 11 68,607,623 12 −0.4 (−0.5, −0.3) 2.4 × 10−23
cg17058475 11 68,607,738 14 −0.4 (−0.5, −0.3) 7.9 × 10−7
cg12556569 11 116,664,040 26 2.4 (1.5, 3.4) 1.4 × 10−2
cg15863539 17 17,716,951 79 0.2 (0.1, 0.3) 1.3 × 10−3
cg20544516 17 17,717,184 73 0.3 (0.2, 0.4) 1.1 × 10−3
cg11024682 17 17,730,095 46 0.5 (0.3, 0.6) 3.8 × 10−11
cg08857797 17 40,927,700 57 0.4 (0.3, 0.6) 7.3 × 10−3
cg03636183 19 17,000,586 68 −0.6 (−0.8, −0.3) 1.3 × 10−2
cg02711608 19 47,287,965 24 −0.3 (−0.4, −0.2) 3.9 × 10−2
cg27243685 21 43,642,367 83 0.4 (0.4, 0.5) 8.4 × 10−20
cg01881899 21 43,652,705 13 0.3 (0.2, 0.3) 1.7 × 10−4
cg06500161 21 43,656,588 60 0.7 (0.6, 0.8) 1.5 × 10−29
LDL-C cg27168858 1 55,351,660 78 0.4 (0.3, 0.6) 5.3 × 10−3
cg00908766 1 109,817,497 59 1.0 (0.6, 1.3) 2.3 × 10−2
cg05119988 4 166,251,190 59 0.5 (0.3, 0.6) 1.4 × 10−4
HDL-C cg17901584 1 55,353,707 53 0.7 (0.5, 0.9) 1.2 × 10−4
cg26313301 19 11,219,616 87 −0.2 (−0.3, −0.1) 3.6 × 10−2
cg27243685 21 43,642,367 83 −0.4 (−0.5, −0.3) 1.2 × 10−9
cg06500161 21 43,656,588 60 −0.7 (−0.8, −0.5) 1.3 × 10−13
aEstimate is the percentage change in DNA methylation per standard deviation change in lipid levels
DNAm DNA methylation
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confirmed an effect of TG on 9 out of 21 EWAS-
identified CpGs (P value <0.05; Additional file 8). For
LDL-C and HDL-C, an effect was found for two of the
three and two of the four CpGs, respectively. Since the
CpGs with higher P values (i.e., lowest level of statistical
evidence) in the EWAS analysis were the ones that did
not survive the MR approach, the multiple testing correc-
tion applied in the EWAS step (PFDR <0.05) for the associ-
ation with lipid levels remains applicable to the MR-
identified CpG set. Interestingly, MR and EWAS estimates
for the effect sizes were highly concordant for the EWAS-
identified CpGs, also for CpGs not statistically significant in
the MR step. The confidence intervals of the MR estimates
were wider, however, in line with the moderate proportion
of variance explained by the PSs (Additional file 9). Post
hoc power calculations [15] were performed for three sce-
narios where the EWAS effect size estimate is (1) the true
causal effect size, (2) half the true causal effect size, and
(3) double the true causal effect size (Additional file 10).
The power estimates indicated that the causal effects we
identified in our MR analysis were the ones for which we
had the highest statistical power.
SNPs in the PS may directly influence DNA methyla-
tion (i.e., a methylation QTL effect) [16], violating the
assumption of MR that the effect is mediated through
lipid levels (Fig. 1c). Of the MR-identified CpGs, three
mapped within 1 Mbp of a PS SNP, for which analyses
were re-run with the SNP added as covariate to the
model (Additional file 11). The association of CpGs
cg12556569 with TG and cg00908766 with LDL-C was
mediated by a direct effect of a PS SNP in cis (rs964184
[mapping 15,121 bp from the CpG] and rs629301
[808 bp from the CpG]). The association of CpG
cg27168858 with LDL-C, however, was not explained by
a nearby PS SNP (rs2479409 [152,989 bp from the
CpG]). Thus, for TG, LDL-C, and HDL-C, eight, one
and two CpGs remained, respectively. Of interest, CpGs
cg06500161 and cg27243685 were associated with both
TG and HDL-C.
Next, we evaluated the possibility that DNA methylation
affected lipid levels, i.e., the reverse of the association im-
plied by the MR analysis. To this end, for every MR-
identified CpG we established the SNP in cis (<100 kb) with
the strongest association with methylation level defined as
the lowest P value (Additional file 12) and used this SNP as
a proxy for DNA methylation (Fig. 1d; Additional file 13).
We found no evidence of an effect of DNA methylation on
lipid levels at these CpGs. In addition to the MR-identified
CpGs, we performed the same analysis for all EWAS-
identified CpGs (Additional files 12 and 13). Two SNPs
could not be evaluated because the SNP was either located
in the CpG site (cg12556569) or was in linkage disequilib-
rium (R2 = 0.52) with a PS SNP (cg00908766), violating MR
assumptions. For all the other six CpGs, no effect of DNA
methylation on lipid levels was found. Thus, no evidence
for an effect on lipid levels was observed for any of the
CpGs (either surviving the previous MR steps or identified
in the initial EWAS analysis) and reverse causation is,
therefore, unlikely.
A final limitation precluding an unequivocal interpre-
tation of the analysis so far is the possibility of pleiotropy.
The SNPs used to construct PSs are primarily, but not
solely, associated with their respective lipid level [11].
Using a multivariable MR analysis with all three lipids
and their PSs (Fig. 1e), we found that the two CpGs
overlapping between TG and HDL-C were driven by
HDL-C while their association with TG could be attri-
buted to pleiotropy (Table 3). For an additional three
CpGs associated with TG, pleiotropic effects could not
be formally excluded (P value >0.05). The effect of TG,
LDL-C, and HDL-C on the remaining three, one, and
two CpGs, respectively, was not driven by pleiotropic ef-
fects. To exclude the occurrence of unmeasured and un-
known pleiotropic effects, we applied Egger regression
[17]. This analysis showed that there was no net pleio-
tropic effect (Table 4). However, while multivariable MR
indicated that the association for the two CpGs overlap-
ping between TG and HDL-C could be attributed to an
effect of HDL-C, Egger regression indicated that it was
due to TG. Table 5 summarizes the outcome from the
sequential steps of our stepwise MR approach on
EWAS-identified CpGs.
The CpGs resulting from the stepwise MR analysis
were annotated to blood cell chromatin states [18],
which inform on the biological role of the genomic re-
gion harboring the CpG. This analysis showed that all
CpGs were located in regulatory regions active in blood
cells (Table 6). To link the differentially methylated
CpGs to a specific gene, we tested for an association be-
tween the methylation level of the six CpGs resulting
from the MR analysis and gene expression in cis
(<100 kb from transcription start site (TSS)). Remark-
ably, all CpGs were associated with gene expression
(P value <0.05; Table 6; Additional file 14) and, in all
cases, it was the gene in which the CpG was located.
The TG-influenced CpGs cg00574958 and cg17058475
(located in a region flanking an active TSS and in an
enhancer, respectively) were both associated with ex-
pression of CPT1A and CpG cg11024682 (located in
an enhancer region) was linked to SREBF1 expression.
The LDL-C-influenced CpG cg27168858 (located in an
active TSS flanking region) mapped to DHCR42. Finally,
the TG- (Egger regression) or HDL-C- (multivariable MR)
influenced CpGs cg06500161 and cg27243685 (located
in a region of weak transcription and flanking an ac-
tive TSS, respectively) were associated with ABCG1
expression. All these genes have a central role in lipid
metabolism.
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Discussion
We performed EWASs of blood lipids in a meta-analysis
comprising 3296 individuals followed by a stepwise MR
approach to evaluate the association of blood lipids with
DNA methylation in circulating immune cells and infer
the direction of causality. Our analysis showed that dif-
ferential methylation was induced by TG at three CpGs,
by LDL-C at one CpG, and by either TG or HDL-C at
two CpGs. We did not observe evidence for the reverse
relationship, that is, an effect of DNA methylation on
lipid levels. These data indicate that blood lipids can epi-
genetically prime immune cells, which may prove rele-
vant for disease phenotypes with an inflammatory
component [4, 5].
All the CpGs we identified mapped to regions with ac-
tive regulatory roles in blood cells and were associated
with the expression of genes with a central role in lipid
metabolism. Higher TG levels induced lower methyla-
tion of CpGs cg00574958 and cg17058475, which was
associated with higher expression of CPT1A. Higher
TG levels also induced higher methylation of CpG
cg11024682, which was associated with lower expres-
sion of SREBF1. CPT1A attaches carnitine to long-chain
fatty acids, which is required for entry into the
mitochondria and subsequent catabolism [19]. SREBF1
regulates energy homeostasis, including genes involved in
the synthesis, import, and efflux of lipids. Sterols, such as
cholesterol, inhibit the effect of SREBF1 [20]. Higher LDL-
C levels induced higher methylation of a CpG in DHCR24,
which was linked to lower DHCR24 expression. DHCR24
catalyzes the reduction of desmosterol to cholesterol, the
last step in the Bloch cholesterol biosynthesis pathway
[21]. Either lower TG or higher HDL-C levels induced
lower methylation of CpGs cg06500161 and cg27243685,
which in turn were associated with higher expression of
ABCG1. ABCG1 mediates cellular cholesterol efflux to
HDL in the reverse cholesterol transport pathway. The
reverse cholesterol transport pathway transfers choles-
terol from peripheral tissues via the blood to the liver
[22]. Taken together, higher TG and LDL-C and lower
HDL-C levels lead to DNA methylation changes that
are associated with, on the one hand, increased catab-
olism and cellular export and, on the other hand, de-
creased cellular import of lipids. These findings
suggest a role for epigenetic priming in end-product
feedback control, a process where the end-product in-
hibits its own synthesis and that has been observed
for cholesterol [23].
Table 3 Estimated effect of TG, LDL-C, and HDL-C levels on DNA methylation using a multivariable MR analysis to exclude
pleiotropic effects
Chromosome Position Mean DNAm (%) Estimate (%/SD)a P value
TG cg00574958 11 68,607,623 12 −0.7 (−1.2, −0.3) 1.5 × 10−3
cg17058475 11 68,607,738 14 −1.0 (−1.6, −0.3) 2.5 × 10−3
cg11024682 17 17,730,095 26 1.0 (0.3, 1.7) 5.4 × 10−3
LDL-C cg27168858 1 55,351,660 78 1.4 (0.5, 2.3) 3.1 × 10−3
HDL-C cg27243685 21 43,642,367 83 −0.7 (−1.1, −0.3) 2.2 × 10−3
cg06500161 21 43,656,588 60 −1.1 (−1.8, −0.5) 3.5 × 10−4
aEstimate is the percentage change in DNA methylation per standard deviation change in lipid levels
DNAm DNA methylation
Table 4 Estimated effect of TG, LDL-C, and HDL-C levels on DNA methylation using an approach based on Egger regression to
exclude pleiotropic effects, including P values for an estimate of net pleiotropic effects of the PS SNPs
Chr Position Mean DNAm (%) Estimate (%/SD)a P value Pleiotropy P value
TG cg00574958 11 68,607,623 12 −1.1 (-1.4, -0.7) 5.7 × 10−9 0.37
cg17058475 11 68,607,738 14 −1.3 (-1.8, -0.8) 2.3 × 10−7 0.82
cg11024682 17 17,730,095 26 0.9 (0.3, 1.5) 1.9 × 10−3 0.50
cg27243685 21 43,642,367 83 0.7 (0.3, 1.1) 6.4 × 10−4 0.18
cg06500161 21 43,656,588 60 1.4 (0.8, 2.0) 2.9 × 10−6 0.75
LDL-C cg27168858 1 55,351,660 78 0.7 (0.1, 1.3) 3.1 × 10−2 0.36
HDL-C cg27243685 21 43,642,367 83 0.3 (-0.9, 1.5) 0.62 0.79
cg06500161 21 43,656,588 60 −0.1 (-1.8, 1.7) 0.93 0.15
aEstimate is the percentage change in DNA methylation per standard deviation change in lipid levels
DNAm DNA methylation
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Our analysis replicated previous EWASs reporting the
association between TG and two CpGs in CPT1A in
CD4+ T cells [7] and whole blood [8]. In addition, eight
out of ten differentially methylated CpGs found in the
most recent EWAS of various blood lipids were repli-
cated [9] (7/8 CpGs replicated for TG, 0/1 for LDL-C, 1/
1 for HDL-C). The CpGs that we did not replicate were
cg20544516 associated with TG (rank 111 in our
analysis, P = 1 × 10−6) and cg22178392 associated with
LDL-C (rank 308,850 in our analysis, P = 0.68). In con-
trast to earlier interpretations of these findings [9], our
MR analysis indicates that differential methylation is the
consequence of inter-individual variation in blood lipid
levels instead of its cause. Interestingly, EWASs of lipid
levels also overlapped with those of other outcomes. An
EWAS of BMI reported differential methylation at
CPT1A and ABCG1 [24], and an EWAS of type 2 dia-
betes at SREBF1 and ABCG1 [25]. Our MR analysis
using polygenic scores of lipid levels predicts that the
altered lipid profile in blood that is associated with BMI
and type 2 diabetes was driving these outcomes.
The stepwise MR approach we implemented circum-
vents various issues commonly encountered in MR. We
used a weighted polygenic score (PS) for the MR analysis
with weights estimated in a large lipid GWAS [11] to
test the hypothesis that lipid levels affected DNA methy-
lation. The PS optimally captured the inter-individual
variance in lipid levels and is less prone to violations of
MR assumptions compared with single genetic variants
[26]. Furthermore, we could exclude the violation of the
assumption in MR that genetic variants in the PS have a
direct effect on DNA methylation by testing the associ-
ation of lipid-associated differential methylation with PS
SNPs in cis. This contrasts with most MR studies where
a direct effect of genetic variants on the outcome is un-
known [12]. Remaining key issues in MR, namely reverse
causation and pleiotropic effects, were addressed using a
bidirectional multivariable model [27] and an approach
based on Egger regression, which accounts for unmeas-
ured and unknown pleiotropic effects [17]. Together
these analyses excluded the occurrence of reverse caus-
ation (here an effect of DNA methylation on lipid levels)
and an involvement of pleiotropy, supporting a causal
role of lipid levels in its association with DNA methyla-
tion in circulating immune cells. Surprisingly, multivari-
able MR and Egger regression yielded opposite results
for the two ABCG1 CpGs that were associated with both
TG and HDL-C. While multivariable MR indicated that
the association could be attributed to an effect of HDL-C,
Egger regression indicated that it was due to TG. These
discrepant outcomes may be indicative of the limits of MR
analysis in the presence of a substantial correlation be-
tween evaluated phenotypes, as is the case for lipid levels.
We presume that the result of the multivariable MR ana-
lysis is closer to the biological mechanism in this case be-
cause the analysis uses the actual measured lipid levels.
Moreover, this interpretation is consistent with the bio-
logical role of ABCG1, which is a key mediator of cellular
cholesterol efflux to HDL particles.
We performed our analysis in a large meta-analysis of
cohorts with matched genotype and genome-wide DNA
methylation data. However, MR analysis has a relatively
low power; the lipid PSs capture only about 5 % of the
total variance in lipid levels. Therefore, we adopted an
approach in which we performed a discovery phase
using a regular EWAS approach followed by validation
Table 5 Overview of the stepwise Mendelian randomization
approach
b c d e
TG cg14476101 ✗
cg19693031 ✓ ✓ ✓ ✗
cg07504977 ✓ ✓ ✓ ✗
cg11376147 ✗
cg00574958 ✓ ✓ ✓ ✓
cg17058475 ✓ ✓ ✓ ✓
cg12556569 ✓ ✗
cg15863539 ✗
cg20544516 ✗
cg11024682 ✓ ✓ ✓ ✓
cg08857797 ✗
cg03636183 ✗
cg02711608 ✗
cg27243685 ✓ ✓ ✓ ✓1
cg01881899 ✓ ✓ ✓ ✗
cg06500161 ✓ ✓ ✓ ✓1
cg06690548 ✗
cg05575921 ✗
cg14817490 ✗
cg06560379 ✗
cg19589396 ✗
LDL-C cg27168858 ✓ ✓ ✓ ✓
cg00908766 ✓ ✗
cg05119988 ✗
HDL-C cg17901584 ✗
cg26313301 ✗
cg27243685 ✓ ✓ ✓ ✓2
cg06500161 ✓ ✓ ✓ ✓2
Starting from associations between lipid levels and DNA methylation, a causal
and unconfounded effect of lipid levels on DNA methylation was estimated
(b), a direct effect of genetic variants on DNA methylation was excluded (c),
reverse causation was excluded (d) and pleiotropy was excluded (e)
A tick indicates a CpG passed step; a cross indicates a CpG failed step
1Egger regression only
2Multivariable MR only
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and causal inference using a stepwise MR approach.
Only for a subset of EWAS findings were we able to
infer the direction of causality in the MR approach.
These were the ones for which our study had a relatively
high statistical power. However, it was striking that the
effect size estimates from the EWASs were generally
highly consistent with those from the MR analysis,
which is compatible with an effect of lipid levels on
DNA methylation for more CpGs. One may argue that
individual steps in our MR approach require additional
multiple testing. This would have further limited our
findings in the multivariable MR approach to those for
LDL-C and HDL-C, for which fewer associated CpGs
were observed and which are thus less affected by add-
itional multiple testing adjustment. We believe that this
would be too conservative, since the association of the
lipid levels with DNA methylation of specific CpGs was
already corrected for multiple testing in the EWAS.
These considerations have two implications. First, larger
studies of blood lipid are expected to detect additional
CpGs influenced by lipid levels. Second, sample sizes
should ideally be increased to achieve sufficient statis-
tical power to directly evaluate the association of PSs
with DNA methylation on a genome-wide scale. This
would remove the necessity of a discovery phase using
EWAS to preserve statistical power and would resolve
the issue pertaining to the question of additional adjust-
ment for multiple testing in a stepwise approach. Sec-
ond, most of the resulting associations will be explained
by an effect of blood lipids on DNA methylation. The
power to test reverse causal relationships (that is of
DNA methylation on blood lipids) can be improved by
the availability of comprehensive catalogues of methyla-
tion QTL enabling testing both in cis and in trans.
Cell counts are known confounders in EWASs meas-
uring whole blood [10, 28] and were included as a covar-
iate in the analyses. However, this also impedes the
discovery of cell type-specific processes. Hence, it re-
mains to be determined if specific immune cells are par-
ticularly prone to epigenetic priming by lipid levels.
However, previous EWASs of lipid levels in adipose
tissue (cg27243685 and cg11024682) and in skin biopsies
(cg11024682) reported differential methylation at CpG
sites also identified in whole blood [9]. This suggests
that the lipid priming does not occur exclusively in
circulating immune cells. A recent study of the TG-
lowering drug fenofibrate suggested that a 3-week daily
treatment was not sufficient to reverse lipid-associated
DNA methylation changes [29] despite the short half-life
of various blood cell types. Together, the presence of
lipid-induced changes across tissues and the inability to
reverse these changes in circulating cells in the short-
term open the possibility that these changes did not
arise in the circulation but occurred already in
hematopoietic stem cells, where lipid priming has previ-
ously been observed [30].
Conclusions
We implemented a systematic MR approach to uncover
the occurrence of epigenetic priming on immune cells
and show that it can be used effectively when genetic
variants for the stimulus of interest are available. Our
findings imply that differential methylation observed in
EWASs may frequently be a consequence rather than a
cause of an outcome of interest. Future studies should
establish whether epigenetic priming plays a role in the
etiological path from risk factor to disease outcome. We
anticipate that with the rapid increase in the availability
of genomics, epigenomics, transcriptomics and metabo-
lomics data, approaches like ours will be increasingly used
to unravel causal relationships in integrative genomics
approaches [14].
Methods
Cohorts
The Biobank-based Integrative Omics Study (BIOS)
Consortium [31, 32] consists of the six Dutch cohorts
Cohort on Diabetes and Atherosclerosis Maastricht
(CODAM) [33], LifeLines (LL) [34], Leiden Longevity
Study (LLS) [35], the Netherlands Twin Register (NTR)
[36], Rotterdam Study (RS) [37], and Prospective ALS
Study Netherlands (PAN) [38]. For all 3296 unrelated
Table 6 DNA methylation of MR-identified CpGs was associated with gene expression of genes involved in lipid metabolism
Chr Position Mean DNAm (%) Gene Estimate (logCPM/β)a P value Chromatin state
TG cg00574958 11 68,607,623 12 CPT1A −3.3 (−4.1,−2.5) 1.5 × 10−14 Flanking active TSS
cg17058475 11 68,607,738 14 CPT1A −1.7 (−2.3,−1.1) 1.8 × 10−8 Enhancer
cg11024682 17 17,730,095 26 SREBF1 −2.4 (−2.8,−2.0) 5.2 × 10−33 Enhancer
LDL-C cg27168858 1 55,351,660 78 DHCR24 −4.1 (−4.9,−3.3) 2.4 × 10−25 Flanking active TSS
HDL-C cg27243685 21 43,642,367 83 ABCG1 −4.5 (−5.4,−3.6) 4.0 × 10−24 Flanking active TSS
cg06500161 21 43,656,588 60 ABCG1 −5.1 (−5.7,−4.5) 1.2 × 10−56 Weak transcription
CpGs are located in regions of active gene regulation
aEstimate is the log counts per million change in gene expression per β (0–1) change in DNA methylation
DNAm DNA methylation
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individuals genotypes, DNA methylation and blood
profiles (including lipid levels and cell counts) were
measured in whole blood, which was collected simulta-
neously for all measurements. RNA-Seq data were also
available for 2044 individuals. DNA methylation and
RNA-Seq data were generated by the Human Genotyp-
ing facility (HugeF) of ErasmusMC, the Netherlands
(http://www.glimdna.org/). Characteristics of the cohorts
can be found in Table 1.
Lipid measurements and cell counts
Triglyceride (TG), HDL cholesterol (HDL-C), and total
cholesterol levels (TC) were measured after a fasting
period of 12 h for CODAM, LL, NTR (for 678/692 indi-
viduals), RS, and PAN; for LLS non-fasted lipids were
measured for 757 of the 785 individuals. LDL cholesterol
(LDL-C) was calculated using Friedewald’s method [39].
For all analyses, TG levels were log-transformed and all
lipid levels were scaled to have mean 0 and standard
deviation 1.
White blood cell counts (WBC), i.e. neutrophils, lym-
phocytes, monocytes, eosinophils, and basophils, were
measured by the standard WBC differential as part of
the complete blood count (CBC). However, a minority
of samples were lacking CBC measurements (15 %) or
did not differentiate between granulocyte subtypes
(neutrophils, eosinophils, and basophils; 37 %). Since
DNA methylation levels are informative for the white
blood cell composition [40], a predictor was built to
infer the white blood cell composition of those samples
using partial least squares, which can handle both multi-
variate responses and high-dimensional covariates. The
R package pls [41] was used to fit the model and to
optimize the number of pls components using fivefold
cross-validation, including age and gender as covariates.
The predictor was trained on two-thirds of the samples
with complete WBC data (N = 1364) and tested on one-
third (N = 682) of samples across cohorts to obtain a val-
idated predictor. The correlations between measured
and predicted leukocyte subtype percentages in the test
set were 0.84, 0.86, and 0.68 for neutrophils, lymphocytes,
and monocytes, respectively. The R code and detailed
documentation for the function wbccPredictor are avail-
able from https://github.com/mvaniterson/wbccPredictor.
Genotypes
SNPs were measured per cohort (for data generation de-
tails see Tigchelaar et al. [34] for LL, Deelen et al. [42]
for LLS, Willemsen et al. [36] for NTR, and Hofman et
al. [37] for RS), harmonized (Genotype Harmonizer [43]),
and imputed (Impute2 [44]) using GoNL5 [45] as refer-
ence. SNPs with an imputation info-score <0.5, Hardy–
Weinberg equilibrium P value <10−4, call rate <95 % or
minor allele frequency <0.05 were removed.
DNA methylation
Using the Zymo EZ DNA methylation kit (Zymo Research,
Irvine, CA, USA), 500 ng of genomic DNA was bisulfite-
converted and 4 μl of bisulfite-converted DNA was measured
on the Illumina 450 k array using the manufacturer’s
protocol (Illumina, San Diego, CA, USA). Quality control
and normalization of the data were done according to
Tobi et al. [46]. In brief, sample outliers were detected and
removed using MethylAid [47] (95 samples removed),
probes with a detection P value >0.01, bead number <3, or
zero intensity were removed, as well as the ambiguously
mapped probes (34,064 probes removed) [48]. This
yielded a set of 453,109 CpGs measured in 3296 samples.
Next, the DNA methylation data were normalized using
the functional normalization [49] approach as implemented
in minfi [50] (with five principal components of the control
probes). Samples where 5 % of the probes failed or probes
where 5 % of the samples failed were excluded (0 samples
and 0 probes removed). The final dataset consisted of
453,109 CpGs from 3296 individuals. The R code for the
quality control and normalization pipeline is available
at https://git.lumc.nl/molepi/Leiden450K.
Gene expression
Total RNA libraries were generated using the TruSeq v2
library protocol and 2 × 50-bp paired-end sequencing was
performed on the Illumina Hiseq2000. Reads passing
Illumina’s Chastity filter were produced using CASAVA
and quality control was done with FastQC [51], cutadapt
[52] (adapter trimming), and Sickle [53] (removal of low-
quality read ends). Reads were aligned to the human
genome (build NCBI37) using STAR [54]. Gene quantifi-
cations were obtained as the total number of reads that
aligned to the exons of a gene as annotated by Ensembl
v.71. Subsequently, gene counts were normalized using
cqn [55] to correct for gene- and sample-specific GC
biases. Linear model fitting and inference were performed
using voom [56] and limma [57]. This resulted in gene
expression data for 2044 of the 3296 individuals (Table 1).
Statistical analysis
All analyses were performed using R [58]. For the EWAS
of lipid levels, the association of DNA methylation with
TG, HDL-C, and LDL-C was evaluated per cohort using
the linear model defined by Eq. 1:
DNAmi ¼ β0 þ β1⋅lipidi þ β2⋅genderi þ β3⋅agei
þ β4⋅%monoi þ β5⋅%lymphi
þ β6⋅%neuti þ β7⋅bisplatei
þ β8⋅positioni þ εi i ¼ 1;…; 3296ð Þ ð1Þ
where %mono, %lymph, and %neut are the percentages
of monocytes, lymphocytes, and neutrophils, bisplate is
the bisulfite plate number, and position is the position
on the 450 k array.
Dekkers et al. Genome Biology  (2016) 17:138 Page 8 of 12
To minimize possible inflation in the test statistic, the
genomic control procedure [59] was applied to achieve
an inflation factor λ of 1.0. Nominal P values and stand-
ard errors were calculated from the resulting corrected
t-statistics. The outcomes of the six cohorts were com-
bined in a fixed-effect meta-analysis using metaphor
[60], followed by genomic control on the resulting z-
statistics (λ = 1.0). P values were calculated from cor-
rected z-values and adjusted for multiple testing using
the Benjamini–Hochberg (FDR) procedure.
Polygenic scores (PSs) were constructed from GWAS
[11] SNPs to serve as an instrument in MR analysis. For
each SNP, dosages were calculated using Eq. 2:
Dosage ¼ 0⋅AAþ 1⋅ABþ 2⋅BB ð2Þ
where AA, AB, and BB are the measured allele
frequencies.
SNPs primarily associated with their respective lipid
level (Additional file 5) were used to calculate the PSs as
defined by Eq. 3:
PS ¼ dosage1⋅ES1 þ dosage2⋅ES2 þ…þ dosageN ⋅ESN
mean ES1; …;N
 
ð3Þ
where ES is the effect size of the reported SNP–lipid
association.
The PSs were scaled to have mean 0 and standard de-
viation 1. The association of the PS with lipid levels was
confirmed using a meta-analysis of the outcomes of a
model similar to the model described in Eq. 1 with PS as
outcome instead of DNA methylation.
MR analysis was done using AER [61]. For each cohort
a two-stage least-squares model (Eq. 4 and Eq. 5), a
model suitable for epidemiological studies [12], was fit-
ted per CpG followed by a meta-analysis of the results.
Stage 1:
predlipidi ¼ γ0 þ γ1⋅PSi þ γ2⋅genderi þ γ3⋅agei
þ γ4⋅%monoi þ γ5⋅%lymphi
þ γ6⋅%neuti þ γ7⋅bisplatei
þ γ8⋅positioni
þ νi i ¼ 1;…; 3296ð Þ ð4Þ
Stage 2:
DNAmi ¼ β0 þ β1⋅predlipidi þ β2⋅genderi
þ β3⋅agei þ β4⋅%monoi
þ β5⋅%lymphi þ β6⋅%neuti
þ β7⋅bisplatei þ β8⋅positioni
þ εi i ¼ 1;…; 3296ð Þ ð5Þ
where predlipid is the predicted lipid level (TG, LDL-C,
HDL-C) based on its polygenic score.
Power calculations for two-stage least-squares-based
MR studies [15] were performed using the R implemen-
tation (https://github.com/kn3in/mRnd).
To address whether the PS SNPs directly affect DNA
methylation as a cis-methylation QTL effect instead of
through an effect on lipid levels, genotypes of SNPs (as
dosage) within 1 Mb of CpGs resulting from the MR
analysis were included as an additional covariate in the
MR model (Eq. 4 and Eq. 5).
To test whether DNA methylation affected lipid levels,
instead of lipid levels affecting DNA methylation (the
direction of the effect evaluated in the PS-based MR
analysis), SNPs were identified that were cis-methylation
QTLs of CpGs associated with lipid levels found using
the model defined by Eq. 6:
DNAmi ¼ β0 þ β1⋅dosagei þ β2⋅genderi
þ β3⋅agei þ β4⋅%monoi
þ β5⋅%lymphi þ β6⋅%neuti
þ β7⋅bisplatei þ β8⋅positioni
þ εi i ¼ 1;…; 3296ð Þ ð6Þ
Subsequently, the dosage of these meQTL SNPs was
entered into the MR model as an instrument for DNA
methylation (Eq. 7 and Eq. 8) and the results were meta-
analyzed.
Stage 1:
predDNAmi ¼ γ0 þ γ1⋅meqtli þ γ2⋅genderi
þ γ3⋅agei þ γ4⋅%monoi
þ γ5⋅%lymphi þ γ6⋅%neuti
þ γ7⋅bisplatei þ γ8⋅positioni
þ νi i ¼ 1;…; 3296ð Þ ð7Þ
Stage 2:
lipidi ¼ β0 þ β1⋅predDNAmi þ β2⋅genderi
þ β3⋅agei þ β4⋅%monoi þ β5⋅%lymphi
þ β6⋅%neuti þ β7⋅bisplatei
þ β8⋅positioni þ εi i ¼ 1;…; 3296ð Þ ð8Þ
where predDNAm is the predicted DNA methylation
level based on its methylation QTL and meqtl is the
dosage of the methylation QTL.
To account for pleiotropic effects (as SNPs in the PSs
are often associated with multiple lipids), multivariable
instrumental variable analysis was done using the three
PSs and three lipids in a two-stage least-squares model
similar to the model defined by Eq. 4 and Eq. 5, followed
by a meta-analysis of the results. This method performs
well for lipid pleiotropy correction [27]. We compared
the multivariable MR approach with an approach based
on Egger regression [17]. For the association between
lipids and PS SNPs required for Egger regression we
used the estimates reported in a GWAS [11] and for the
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association between PS SNPs and DNA methylation we
used Eq. 9. We combined the results in a meta-analysis.
DNAmi ¼ γ0 þ γ1⋅dosagei þ γ2⋅genderi
þ γ3⋅agei þ γ4⋅%monoi
þ γ5⋅%lymphi þ γ6⋅%neuti
þ γ7⋅bisplatei þ γ8⋅positioni
þ νi i ¼ 1;…; 3296ð Þ ð9Þ
DNA methylation was associated with expression of
genes within 100 kb in limma [57] using the linear
model defined by Eq. 10 per cohort, after which the re-
sults were meta-analyzed.
Expressioni ¼ β0 þ β1⋅DNAmi þ β2⋅genderi
þ β3⋅agei þ β4⋅%monoi
þ β5⋅%lymphi þ β6⋅%neuti
þ β7⋅bisplatei þ β8⋅positioni
þ flowcelli þ εi i ¼ 1;…; 2044ð Þ ð10Þ
where flowcell is the Hiseq2000 flowcell.
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